Chemistry:Galunisertib
From HandWiki
Short description: Chemical compound
 | |
| Clinical data | |
|---|---|
| Routes of administration | PO |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| Chemical and physical data | |
| Formula | C22H19N5O |
| Molar mass | 369.428 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Galunisertib (LY2157299) is a small molecular experimental cancer drug previously in development by Eli Lilly. It is a TGF-b inhibitor.[1] Development of galunisertib by Eli Lilly was discontinued in January 2020.[2]
Galunisertib was investigated in a phase II trial for treatment of hepatocellular carcinoma.[3] Pre-clinically, combination of galunisertib with PD-L1 blockade resulted in improved tumor growth inhibition.[4]
References
- ↑ "Lilly Oncology Pipeline - Lilly USA". http://www.lillyoncologypipeline.com/molecule/tgf-beta-r-1-kinase-inhibitor/overview.
- ↑ "Eli Lilly cuts 3 cancer drugs amid Q4 clear-out". https://www.fiercebiotech.com/biotech/eli-lilly-cuts-three-cancer-drugs-amid-q4-clear-out.
- ↑ Clinical trial number NCT01246986 for "A Study of LY2157299 in Participants With Hepatocellular Carcinoma" at ClinicalTrials.gov
- ↑ "Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade". Journal for Immunotherapy of Cancer 6 (1): 47. June 2018. doi:10.1186/s40425-018-0356-4. PMID 29866156.
 |  |
